MiMedx Group, Inc. (MDXG)
| Market Cap | 666.85M -35.4% |
| Revenue (ttm) | 355.17M -2.4% |
| Net Income | 6.24M -80.6% |
| EPS | 0.04 -80.1% |
| Shares Out | 145.76M |
| PE Ratio | 108.83 |
| Forward PE | 183.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 978,892 |
| Open | 4.690 |
| Previous Close | 4.640 |
| Day's Range | 4.485 - 4.690 |
| 52-Week Range | 3.025 - 7.970 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 7.40 (+61.75%) |
| Est. Earnings | Oct 28, 2026 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The co... [Read more]
Financial Performance
In 2025, MiMedx Group's revenue was $418.63 million, an increase of 19.99% compared to the previous year's $348.88 million. Earnings were $48.58 million, an increase of 14.52%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price target is $7.4, which is an increase of 61.75% from the latest price.
News
MiMedx announces ‘favorable’ federal court ruling on Axiofill
MiMedx (MDXG) Group announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the company’s litigation challenging the FDA regulatory classification of A...
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following ...
MiMedx price target raised to $8 from $6 at Craig-Hallum
Craig-Hallum raised the firm’s price target on MiMedx (MDXG) to $8 from $6 and keeps a Buy rating on the shares. The pending acquisition of Sanara MedTech (SMTI) gives the…
MiMedx price target raised to $7 from $5 at Lake Street
Lake Street analyst Brooks O’Neil raised the firm’s price target on MiMedx (MDXG) to $7 from $5 and keeps a Buy rating on the shares after the company agreed to…
MiMedx to acquire Sanara MedTech for $35 per share, $350M enterprise value
MiMedx Group (MDXG) and Sanara MedTech (SMTI) announced that they have entered into a definitive merger agreement under which MiMedx will acquire all of the outstanding shares of Sanara in…
MiMedx reports Q2 EPS (5c), consensus (3c)
Reports Q2 revenue $64.36M, consensus $63.46M. Joseph H. Capper, MiMedx (MDXG) Chief Executive Officer, commented, “During the second quarter, we delivered another strong performance in our Surgical f...
MiMedx Group Earnings Call Transcript: Q2 2026
Announced acquisition of Sanara MedTech, creating a leading regenerative medicine company with a strong surgical focus. Q2 2026 saw sequential recovery in wound care and 15% year-over-year growth in surgical, with net sales of $64 million. Combined company expects over $400 million revenue and 20%+ adjusted EBITDA margin in 2027.
MiMedx Group Quarterly report: Q2 2026
MiMedx Group has published its Q2 2026 quarterly earnings report on July 29, 2026.
MiMedx Group Earnings release: Q2 2026
MiMedx Group released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
MiMedx Group Press release: Q2 2026
MiMedx Group issued a press release on July 29, 2026, disclosing material business information to investors.
MiMedx Group Slides: Q2 2026
MiMedx Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
Reports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 2...
MIMEDX to Acquire Sanara MedTech
Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX's Strategic Priority to Expand Surgical Footprint, Nearly Doubli...
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second qu...
MiMedx Group Transcript: AGM 2026
The meeting covered director elections, executive compensation approval, and auditor ratification. Management discussed the impact of Medicare reform, cost reductions, and growth in the surgical segment, along with regulatory and capital initiatives. No shareholder questions were submitted.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum...
MIMEDX Announces Launch of G4Derm® Plus
Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx...
MiMedx price target lowered to $6 from $7 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on MiMedx (MDXG) to $6 from $7 and keeps a Buy rating on the shares. The firm cites MiMedx’s Q1 results and guidance, which…
MiMedx price target lowered to $6 from $7 at Citizens
Citizens lowered the firm’s price target on MiMedx (MDXG) to $6 from $7 and keeps an Outperform rating on the shares. MiMedx is navigating a difficult 2026 transition year due…
MiMedx reports Q1 adjusted EPS (5c), consensus (4c)
Reports Q1 revenue $58.99M, consensus $65.8M. Joseph H. Capper, MiMedx (MDXG) Chief Executive Officer, commented, “The first quarter of 2026 was adversely impacted as new Medicare reimbursement polici...
MiMedx Group Earnings Call Transcript: Q1 2026
Q1 2026 saw net sales drop 33% year-over-year, driven by a 60% decline in wound care due to Medicare reimbursement changes, while surgical sales grew 13%. A $40 million cost reduction was implemented, and guidance anticipates sequential recovery and a return to profitability in the second half of the year.
MiMedx Group Quarterly report: Q1 2026
MiMedx Group has published its Q1 2026 quarterly earnings report on April 29, 2026.
MiMedx Group Earnings release: Q1 2026
MiMedx Group released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
MIMEDX Announces First Quarter 2026 Operating & Financial Results
Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29,...